ArticleVeterinary world2025
Copper nanoparticles as a novel therapeutic approach for canine distemper virus: Clinical, hematological, and biochemical evidence from naturally infected dogs.
Article in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Canine distemper virus (CDV) remains a major cause of morbidity and mortality in dogs worldwide, particularly in unvaccinated populations. Current therapeutic options are largely supportive, with no widely available effective antiviral treatment. Nanotechnology-based therapies, such as copper nanoparticles (CuNPs), have recently shown promise against a range of viral pathogens. This study aimed to evaluate the clinical efficacy and safety of CuNPs in naturally infected dogs with CDV and to assess their effects on hematological and biochemical parameters. Materials and Methods: A total of 28 mixed-breed dogs (aged 2-8 months) were enrolled between January and February 2024. Clinical suspicion of CDV was confirmed by rapid immunochromatographic testing and reverse transcription polymerase chain reaction (RT-PCR) targeting the Results: CDV was detected in 65% (15/23) of clinically suspected dogs by RT-PCR. Treated dogs demonstrated marked improvement in clinical signs, with complete recovery in all non-neurological cases and a 75% recovery rate in neurological cases. Hematological analyses revealed significant increases (p < 0.05) in red blood cell count, hemoglobin, packed cell volume, platelet count, white blood cell count, and lymphocyte count in CuNP-treated dogs compared with untreated controls. Serum biochemistry showed reductions in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, blood urea nitrogen, and creatinine, alongside improved albumin levels after treatment. No adverse effects were observed during or after therapy. Conclusion: CuNPs demonstrated significant antiviral activity and clinical benefit in dogs naturally infected with CDV. The findings suggest that CuNPs may represent a promising adjunctive therapy for canine distemper. However, larger controlled trials are warranted to validate efficacy, optimize dosing, and ensure long-term safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.